Simple Summary Glioblastoma (GBM) is the most common malignant primary brain tumor.
Although the standard of care, including maximal resection, concurrent radiotherapy with …

Despite major advances in therapy, cancer continues to be a leading cause of mortality. In
addition, toxicities of traditional therapies pose a significant challenge to tolerability and …

Abstract Background Tumor-Treating Fields (TTFields) is an emerging treatment modality for
glioblastoma (GBM). Studies have shown a good safety profile alongside improved efficacy …

Introduction As a novel treatment modality, tumor treating fields (TTFields) exert low-
intensity, medium-frequency electric fields on tumor cells. TTFields' effectiveness and safety …

Opinion statement Glioblastoma is a deadly disease and even aggressive neurosurgical
resection followed by radiation and chemotherapy only extends patient survival to a median …

Glioblastoma (GBM) is a devastating brain tumor with poor prognosis despite advances in
surgery, radiation, and chemotherapy. Survival of patients with glioblastoma remains poor …

Introduction: Local control is fundamental, both for the curative as well as the palliative
treatment of cancer. Tumor treating fields (TTFields) are low intensity (1–2 V/cm) …

Tumor treating fields (TTFields) is a noninvasive, regional antimitotic treatment modality that
has been approved for the treatment of recurrent glioblastoma by the US FDA and has a CE …

Glioblastoma (GBM) is a challenging cancer with poor prognosis. The classical standard for
treatment is safe resection, followed by concurrent chemoradiotherapy with subsequent …

Although major innovations in treatment are advancing, cancer persists as one of the
leading causes of mortality. With the rising incidence of cancer and as we treat them …